View item

US National Institutes of Health – Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed) – PA-18-868
Sponsor: US National Institutes of Health 		Closing Date: 05-Feb-2019
Genome-wide association studies and other disease studies have found many variants that are statistically associated with disease risk, disease protection, or other traits. However, such studies do not show which variants in genomic elements cause these effects, or how they result in differences in function. Similarly, clinical genomic sequencing studies have identified many variants in healthy and diseased individuals. However, the pathogenicity of such variants is often unknown, leading to their classification as variants of uncertain significance (VUS), which makes clinical implementation difficult. This FOA aims to support research that develops novel, transformative, and generalizable genomic approaches to study the functional and disease effects of genomic variation, specifically how differences in sequence lead to differences in genome function, and to better understand how functional differences lead to disease risk or traits, or how to this knowledge can be used clinically. These new approaches could fall into a range of activities, from exploring novel concepts, developing new methods, or developing new ways to analyze data that will substantially advance the ability to understand the functional consequences of sequence variation and provide fundamental knowledge to directly or indirectly accelerate scientific and medical breakthroughs that improve human health.

Eligibility
• Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
• Applications from Foreign Organizations: Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.

Funding
• Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting USD $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/Research Contact at the NIH at least 6 weeks before submitting the application.
• The scope of the proposed project should determine the project period. The maximum project period is 4 years.

Please see the Funding Opportunity Announcement for further information. Applications may be prepared and submitted via the NIH ASSIST system or Grants.gov. For complete instructions, you must refer to both the NIH Application Guide and the Funding Opportunity Announcement (FOA), noting that instructions in the FOA take precedence over the Application Guide.

Key Dates
Letter of Intent (non-mandatory) due to NIH: Not Applicable
Applications due to UQR&I: 22 January 2019
Applications close with NIH: 5 February 2019, 5:00pm local time of applicant organisation
Future application closing dates: Standard dates apply until expiry
Expiration date of FOA: 6 July 2021

Ahead of internal review, ensure all online components on ASSIST or Grants.gov are complete. To initiate review, email your completed Funding Application Coversheet to internationalgrants@research.uq.edu.au. Interested applicants are strongly encouraged to make contact with the UQR&I international team (via internationalgrants@research.uq.edu.au) well in advance of the UQR&I internal deadline to discuss their application.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-18-868.html

Return